Theratechnologies Inc. announced the publication of a peer-reviewed article in Frontiers in Immunology that enhances understanding of the molecular mechanism of action of sudocetaxel zendusortide (also known as TH1902) as a potential anticancer treatment. Sudocetaxel zendusortside is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor (SORT1) and expedites the internalization and delivery of the cytotoxic payload (docetaxel) directly into cancer cells. The article, "Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing" appears in the "Cancer Immunity and Immunotherapy" section of the February (Volume 15) issue of the journal.

Most cancers of breast, ovary, prostate, pancreas, and brain (e.g., glioblastoma [GBM) are cold tumors, and are largely treated with traditional therapies like radiation and chemotherapy. As a result, researchers have sought to understand how to turn cold tumors hot by reversing the suppressive microenvironment surrounding cold tumors and by attracting more of the "right" anti-tumor lymphocytes. Sudocetaxel ZendUSortide is a first-of-its-kind sortilin receptor (Sort1)-targeting PDC, and the first compound to emerge from the Company's broader licensed oncology platform.

As a new chemical entity, sudocetaxel z endusortide employs a cleavable linker to conjugate (attach) a proprietary peptide to docetaxel, a well-established cytotoxic chemotherapeutic agent used to treat many cancers. The FDA granted Fast Track designation to sudocetaxel z Endusortide as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy. SudocetaxelZendusortide is currently being evaluated in a Phase 1 clinical trial in individuals with advanced ovarian cancer.

Theratechnologies has established the SORT1+ TechnologyTM platform as an engine for the development of PDCs that target SORT1, which is expressed in multiple tumor types. SORT1 is a "scavenger" receptor that plays a significant role in protein internalization, sorting, and trafficking. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the combination of sudocetaxel Zendusorts ide with anti-PD-L1 checkpoint inhibitor therapy which may yield improved clinical outcomes, the potential treatment of various types of cancer with sudocetaxel zENDusortide, the development of PDCs resulting from the SORT1+ Technology??

platform and estimates regarding the expression of SORT1 in various types of cancer.